A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes (T2D) and obesity has sparked considerable efforts to develop next-generation co-agonists that are more effective. We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Hongwei, Pang, Shuguang, Zhang, Yawei, Yu, Ting, Liu, Meng, Deng, Huan, Li, Li, Feng, Liqi, Song, Baili, Han-Zhang, Han, Ma, Qingyang, Qian, Lei, Yang, Wenying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232612/
https://www.ncbi.nlm.nih.gov/pubmed/35750681
http://dx.doi.org/10.1038/s41467-022-31328-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232612/
https://www.ncbi.nlm.nih.gov/pubmed/35750681
http://dx.doi.org/10.1038/s41467-022-31328-x

Ejemplares similares